S100B and brain injury: In a review from 2017 [47], the authors consider the applicability of S100b protein as a biomarker in different clinical scenarios, such as stratification and discharge destination in patients with mild TBI, as well as the need for CT in this patient group, prognostic prediction in patients with moderate to severe TBI, progression of secondary injuries, and monitoring of therapeutic strategies in patients with acute brain injuries.